LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Year: 2023
Type: conference-abstract
Source: Annals of Oncology
Institutions: Dana-Farber Cancer Institute, Tennessee Oncology, University of Miami Health System, Beth Israel Deaconess Medical Center, Cedars-Sinai Medical Center, Massachusetts General Hospital, The Barbara Ann Karmanos Cancer Institute, University of Southern California, Swedish Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Merck, Sanofi, American Society of Clinical Oncology, F. Hoffmann-La Roche, Associazione Italiana di Oncologia Medica, Exelixis, Society for Immunotherapy of Cancer, PTC Therapeutics, Arrowhead Pharmaceuticals, Mylan, Jounce Therapeutics, Incyte, Calithera Biosciences, Seagen, Invitae, European Association of Urology, Eisai, Astellas Pharma, European Society for Medical Oncology, Ipsen, EUSA Pharma, Genentech, EMD Serono, Merck Sharp and Dohme, Daiichi Sankyo Europe
OpenAlex ID: W4387809606